Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
-0.79 (-0.45%)
Real-time:   3:54PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 168.52 - 176.23
52 week 72.13 - 184.49
Open 172.20
Vol / Avg. 1.02M/1.67M
Mkt cap 22.40B
P/E 121.19
Div/yield     -
EPS 1.44
Shares 128.40M
Beta 0.55
Inst. own 112%
Jul 23, 2014
Q2 2014 Illumina Inc Earnings Call - 5:00PM EDT - Add to calendar
Jul 23, 2014
Q2 2014 Illumina, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Jun 11, 2014
Illumina, Inc. at Goldman Sachs Healthcare Conference - Webcast
Jun 3, 2014
Illumina, Inc. at Bank of America Merrill Lynch Global Technology Conference - Webcast
May 28, 2014
Illumina, Inc. Annual Shareholder Meeting - Webcast
May 13, 2014
Illumina, Inc. at Bank of America Merrill Lynch Health Care Conference - Webcast
Apr 22, 2014
Q1 2014 Illumina, Inc. Earnings Conference Call - Webcast
Apr 22, 2014
Q1 2014 Illumina, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 14.25% 8.82%
Operating margin 21.89% 9.44%
EBITD margin - 24.77%
Return on average assets 7.92% 4.49%
Return on average equity 15.49% 8.79%
Employees 3,000 -
CDP Score - -


5200 Illumina Way
United States - Map
+1-858-2024500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. In February 2014, Illumina, Inc. announced that Novogene purchased one HiSeq X Ten. In March 2014, WuXi Genome Center has purchased Illumina HiSeq X Ten sequencing system.

Officers and directors

William H. Rastetter Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Francis A. deSouza President, Director
Age: 43
Bio & Compensation  - Reuters
Jay T. Flatley Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marc A. Stapley Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
David R. Walt Ph.D. Chairman - Scientific Advisory Board, Independent Director
Age: 61
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Christian O. Henry Senior Vice President, Chief Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Nicholas J. Naclerio Ph.D. Senior Vice President, Corporate Development & General Manager - Enterprise Informatics
Age: 41
Bio & Compensation  - Reuters
Tristan B. Orpin Senior Vice President & General Manager, Reproductive and Genetic Health
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance